◆英語タイトル:Circassia Pharmaceuticals Plc (CIR) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011229
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月22日
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Circassia Pharmaceuticals plc (Circassia) develops treatments for allergy and respiratory diseases such as asthma. The company’s product line includes NIOX, which is used to improve asthma management by assisting in diagnosis. In addition, the company’s pipeline includes a number of inhaled medicines for chronic obstructive pulmonary disease (COPD) treatment, including single and combination dose products. Circassia’s products find application in the treatment of allergies and autoimmune conditions caused by cat, house dust mite, grass and ragweed. The company caters to allergy and asthma specialists in the US, the UK, Germany and other countries through its network of partners. Circassia is headquartered in Oxford, England, the UK.
Circassia Pharmaceuticals Plc (CIR) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Circassia Pharmaceuticals Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
Circassia Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Circassia Pharmaceuticals Plc, Medical Equipment, Deal Details 11
Asset Purchase 11
Aerocrine Acquires FENO Assets From FILT 11
Venture Financing 12
Prosonix Raises Additional US$9 Million In Series B Financing Round 12
Partnerships 14
Circassia Pharma Enters into Licensing Agreement with NanoPass Technologies 14
Aerocrine Enters Into Licensing Agreement With Medisoft 15
NanoPass Technologies Enters Into Licensing Agreement With Circassia 16
Aerocrine Enters Into Distribution Agreement With Shanghai Pharma For Niox Mino And Test Kits 17
Aerocrine Enters Into Distribution Agreement With Stallergenes For Niox Mino 18
Centre of Excellence for Prevention of Organ Failure Enters Into Co-Development Agreement With Adiga Life Sciences For Proteomic And Genomic Biomarkers 19
Aerocrine Enters Into Co-Development Agreement With FILT 20
Equity Offering 21
Aerocrine Raises USD60 Million in Rights Offering of Shares 21
Aerocrine Completes Private Placement Of Shares For US$15 Million 23
Aerocrine Completes Rights Offering Of Common Stock For US$36 Million 24
Acquisition 25
Circassia Pharmaceuticals Acquires Aerocrine 25
Circassia Pharma Acquires Prosonix for USD157.6 Million 27
Circassia Pharmaceuticals Plc – Key Competitors 29
Circassia Pharmaceuticals Plc – Key Employees 30
Circassia Pharmaceuticals Plc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Sep 27, 2017: Circassia Pharmaceuticals: Interim Results for the Six Months Ended 30 June 2017 32
Apr 25, 2017: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2016 33
Mar 11, 2016: Circassia Pharmaceuticals: Preliminary Results for the Year Ended 31 December 2015 34
Corporate Communications 35
Apr 25, 2017: Circassia Announces Non-Executive Director Retirements 35
Government and Public Interest 36
Nov 29, 2017: Circassia Welcomes New NICE Guidelines Recommending Use of FeNO Testing in Asthma Diagnosis 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Tables
Circassia Pharmaceuticals Plc, Medical Equipment, Key Facts, 2016 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
Circassia Pharmaceuticals Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
Circassia Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
Circassia Pharmaceuticals Plc, Deals By Market, 2011 to YTD 2017 8
Circassia Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Aerocrine Acquires FENO Assets From FILT 11
Prosonix Raises Additional US$9 Million In Series B Financing Round 12
Circassia Pharma Enters into Licensing Agreement with NanoPass Technologies 14
Aerocrine Enters Into Licensing Agreement With Medisoft 15
NanoPass Technologies Enters Into Licensing Agreement With Circassia 16
Aerocrine Enters Into Distribution Agreement With Shanghai Pharma For Niox Mino And Test Kits 17
Aerocrine Enters Into Distribution Agreement With Stallergenes For Niox Mino 18
Centre of Excellence for Prevention of Organ Failure Enters Into Co-Development Agreement With Adiga Life Sciences For Proteomic And Genomic Biomarkers 19
Aerocrine Enters Into Co-Development Agreement With FILT 20
Aerocrine Raises USD60 Million in Rights Offering of Shares 21
Aerocrine Completes Private Placement Of Shares For US$15 Million 23
Aerocrine Completes Rights Offering Of Common Stock For US$36 Million 24
Circassia Pharmaceuticals Acquires Aerocrine 25
Circassia Pharma Acquires Prosonix for USD157.6 Million 27
Circassia Pharmaceuticals Plc, Key Competitors 29
Circassia Pharmaceuticals Plc, Key Employees 30
Circassia Pharmaceuticals Plc, Subsidiaries 31